Under Rs 100: Aluminium Pharma Foils Manufacturer Reports 314 Per cent Growth in Monthly Sales in October; Stock Rallies Around 5 Per cent Today

Under Rs 100: Aluminium Pharma Foils Manufacturer Reports 314 Per cent Growth in Monthly Sales in October; Stock Rallies Around 5 Per cent Today

The company’s shares have delivered an impressive return of over 165 per cent to its shareholders.

GSM Foils Ltd is a micro-cap company that specializes in the manufacturing of blister foils and aluminium pharma foils for pharmaceutical packaging, offers products ranging from 20 to 40 microns in thickness, suitable for coated, poly-laminated, blister, and printed foils.

The company’s stock rallied around 5 per cent today after updating its monthly sales volume with significant trading volumes. According to the company's latest announcement, their sales volume for October 2024 reached Rs 11,87,53,378 compared to Rs 2,86,90,409 representing a growth of 313.91 per cent. Net Sales for April-October 2024 stands at Rs 64,04,72,682.

Currently, the company’s shares are trading at around Rs 85.80 per share on the NSE. The company’s current market capitalization stands at Rs 109.92 crore. additionally, the shares have delivered a multibagger return of over 165 per cent compared to the final IPO issue price.

DSIJ's ‘Penny Pick’ service provides research-backed penny stock recommendations below Rs. 100. If this interests you, do download the service details here.

The company’s IPO launched in May 2024 at Rs 32 each with a face value of Rs 10 each. The promoter holding pre-IPO was 99.99 per cent which is now reduced to 73.14 per cent after the IPO.

The company operates a 7,973-square-foot manufacturing facility located in the Sapphire Building in Thane, Vasai, Maharashtra. This ground-plus three-floor facility is fully equipped to handle all aspects of the production process, including seamless manufacturing, quality testing, research, storage, and packaging. In terms of revenue distribution, blister foils contribute 63 per cent of the company's revenue, while pharma foils account for the remaining 37 per cent. Geographically, the company has a strong presence across India, serving clients in 13 states and one Union Territory.

Investors must keep this penny stock on their radar.

Disclaimer: The article is for informational purposes only and not investment advice.

Rate this article:
5.0

DSIJ MINDSHARE

Mkt Commentary20-Dec, 2024

Swing Trading22-Dec, 2024

IPO Analysis20-Dec, 2024

Mindshare20-Dec, 2024

IPO Analysis20-Dec, 2024

Knowledge

MF15-Nov, 2024

General15-Nov, 2024

MF14-Nov, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR